Chairman: Kevin Johnson

Advent Contact: Raj Parekh

First-in-class biopharmaceutical for treating osteoarthritis

Levicept is developing a biological fusion protein, p75NTR-Fc, comprising the endogenous human neurotrophin receptor and an immunoglobulin Fc fragment, for treating chronic pain in patients with osteoarthritis.

Advent invested in the Series A in 2014.

Back